As an agonist of TLR4, administration of LPS (3 mg·kg−1 per single injection) in HCC mice only aimed to reverse the geniposide‐induced inhibition of TLR4, instead of endotoxin‐triggered HCC progression in this study (Kitamura et al., 2002). This evidence concerns the gene TLR4 and hepatocellular carcinoma.